Institutional Hospital Injectables & Injectable Anesthetics
Provider Blau Farmacêuticablau.com
Founded —
Sells To —
Pricing Model —
Ownership —
Blau Farmacêutica's institutional line of hospital injectables and injectable anesthetics, serving hospitals across Brazil and the SUS system.
Blau Farmacêutica's institutional segment line produces hospital injectables and injectable anesthetics at its Cotia industrial complex, alongside muscle relaxants and other high-complexity hospital specialties. The line serves more than 6,000 hospitals, including Brazil's public SUS system.
It competes directly with Cristália's Hospital Anesthetics & Hospital Injectables offering in the Brazilian hospital channel.
| Attribute | Institutional Hospital Injectables & Injectable Anesthetics | Hospital Anesthetics & Hospital Injectables | |
|---|---|---|---|
| Provider | |||
| Founded | — | 1972 | |
| Sells To | — | Consumers, Hospitals | |
| Pricing Model | — | Product Sales | |
| Ownership | — | Private |
Provider Blau Farmacêuticablau.com
Founded —
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 1972
Sells To Consumers, Hospitals
Pricing Model Product Sales
Ownership Private


Hypofarma's injectable portfolio of anesthetics and hospital injectables, including hyperbaric bupivacaine, ropivacaine, and ICU ampoules.


Eurofarma's Hospitalar unit supplying hospital medicines and large-volume parenteral solutions, including anesthetics, to Brazilian hospitals.


EMS's hospital unit supplying medicines and solutions to hospitals and institutional healthcare buyers, reinforced by a 2026 injectables acquisition.


Aesthetic injectables line marketing botulinum toxin BTXA and STYLAGE dermal fillers to Brazilian aesthetic clinicians.
Hypofarma's injectable portfolio of anesthetics and hospital injectables, including hyperbaric bupivacaine, ropivacaine, and ICU ampoules.

Eurofarma's Hospitalar unit supplying hospital medicines and large-volume parenteral solutions, including anesthetics, to Brazilian hospitals.

EMS's hospital unit supplying medicines and solutions to hospitals and institutional healthcare buyers, reinforced by a 2026 injectables acquisition.

Aesthetic injectables line marketing botulinum toxin BTXA and STYLAGE dermal fillers to Brazilian aesthetic clinicians.
